Abbott Laboratories insider plans sale of common shares

Abbott Laboratories (ABT) reported a planned sale of common stock under a Form 144.

Rhea-AI Filing Summary

Abbott Laboratories (ABT) reported a planned sale of common stock under a Form 144. A brokerage account at UBS Financial Services is listed in connection with 5,850 shares of common stock to be sold on the NYSE on or after August 11, 2026. The filing also references vested restricted stock awards dated February 27, 2026 in amounts of 1,960, 1,991, and 1,899 shares as the source of the securities to be sold.

Key Figures

Planned shares to be sold: 5,850 shares Restricted stock award vested: 1,960 shares Restricted stock award vested: 1,991 shares +1 more

4 metrics

Planned shares to be sold 5,850 shares Common stock associated with UBS Financial Services for sale on or after August 11, 2026

Restricted stock award vested 1,960 shares Common stock from Restricted Stock Award Vested on February 27, 2026

Restricted stock award vested 1,991 shares Common stock from Restricted Stock Award Vested on February 27, 2026

Restricted stock award vested 1,899 shares Common stock from Restricted Stock Award Vested on February 27, 2026

Key Terms

Form 144, Restricted Stock Award Vested, common stock

3 terms

Form 144 regulatory

"Abbott Laboratories (ABT) reported a planned sale of common stock under a Form 144."

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Award Vested financial

"Common | 02/27/2026 | Restricted Stock Award Vested | Issuer"

common stock financial

"The filing links three vested restricted stock awards to the sale of common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Abbott Laboratories (ABT) disclose in this Form 144?

Abbott Laboratories discloses a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, with the shares originating from vested restricted stock awards dated February 27, 2026.

How many Abbott (ABT) shares are linked to vested restricted stock awards?

The filing links three vested restricted stock awards dated February 27, 2026 to the sale: 1,960 shares, 1,991 shares, and 1,899 shares of Abbott common stock as securities available to be sold.

Which broker is handling the planned sale of ABT shares?

The planned sale of Abbott (ABT) common stock is associated with UBS Financial Services, Inc., located at 1000 Harbor Blvd., Weehawken, NJ, as the brokerage firm involved in the Form 144 filing.

On which exchange are the Abbott (ABT) shares expected to be sold?

The Form 144 indicates that Abbott Laboratories common shares are expected to be sold on the NYSE, with the prospective sale date noted as August 11, 2026, subject to typical Form 144 conditions.

What types of securities are being reported in Abbott’s (ABT) Form 144?

The Form 144 reports common stock of Abbott Laboratories. The securities to be sold arise from Restricted Stock Award Vested transactions dated February 27, 2026, which produced the shares eligible for resale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2026 - 06:22 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001867666
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ABBOTT LABORATORIES
SEC File Number	001-02189
Address of Issuer	100 ABBOTT PARK ROAD ABBOTT PARK ILLINOIS 60064
Phone	(224) 667-6100
Name of Person for Whose Account the Securities are To Be Sold	Louis H. Morrone
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 1000 Harbor Blvd. 3rd Floor Weehawken NJ 07086	5850	642506	1730383296	08/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/27/2026	Restricted Stock Award Vested	Issuer			1960	08/11/2026	N/A
Common	02/27/2026	Restricted Stock Award Vested	Issuer			1991	08/11/2026	N/A
Common	02/27/2026	Restricted Stock Award Vested	Issuer			1899	08/11/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Louis H. Morrone, by Aaron N. Rice, Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)